Format

Send to

Choose Destination
Epigenetics. 2019 Mar 14:1-18. doi: 10.1080/15592294.2019.1588682. [Epub ahead of print]

DNA methylation changes associated with Parkinson's disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood.

Author information

1
a Biodesign Institute , Arizona State University , Tempe , AZ , USA.
2
b Neurogenomics Division , Translational Genomics Research Institute , Phoenix , AZ , USA.
3
c Center for Computational Biology & Bioinformatics, Department of Medicine , University of California San Diego , La Jolla , CA , USA.
4
d Center for Bioinformatics and Genomics Systems Engineering, Texas A&M Engineering Experiment Station , Texas A&M University , College Station , TX , USA.
5
e Advanced Center for Parkinson's Disease Research and Precision Neurology Program, Harvard Medical School , Brigham & Women's Hospital , Boston , MA , USA.
6
f Genomics Center, Institute for Genomics Medicine , University of California San Diego , La Jolla , CA , USA.
7
g Harvard Biomarkers Study investigators are listed in the Acknowledgement section.
8
h Department of Neurosciences , University of California San Diego , La Jolla , CA , USA.
9
i Department of Pathology , University of California San Diego , La Jolla , CA , USA.

Abstract

Parkinson's Disease (PD) is a common neurodegenerative disorder currently diagnosed based on the presentation of characteristic movement symptoms. Unfortunately, patients exhibiting these symptoms have already undergone significant dopaminergic neuronal loss. Earlier diagnosis, aided by molecular biomarkers specific to PD, would improve overall patient care. Epigenetic mechanisms, which are modified by both environment and disease pathophysiology, are emerging as important components of neurodegeneration. Alterations to the PD methylome have been reported in epigenome-wide association studies. However, the extent to which methylation changes correlate with disease progression has not yet been reported; nor the degree to which methylation is affected by PD medication. We performed a longitudinal genome-wide methylation study surveying ~850,000 CpG sites in whole blood from 189 well-characterized PD patients and 191 control individuals obtained at baseline and at a follow-up visit ~2 y later. We identified distinct patterns of methylation in PD cases versus controls. Importantly, we identified genomic sites where methylation changes longitudinally as the disease progresses. Moreover, we identified methylation changes associated with PD pathology through the analysis of PD cases that were not exposed to anti-parkinsonian therapy. In addition, we identified methylation sites modulated by exposure to dopamine replacement drugs. These results indicate that DNA methylation is dynamic in PD and changes over time during disease progression. To the best of our knowledge, this is the first longitudinal epigenome-wide methylation analysis for Parkinson's disease and reveals changes associated with disease progression and in response to dopaminergic medications in the blood methylome.

KEYWORDS:

DNA methylation; Parkinson’s disease; biomarkers; blood epigenome; disease progression; dopamine replacement therapy; longitudinal; one-carbon metabolism

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center